Cancer Genetics Inc (NASDAQ:CGIX) shares gapped down prior to trading on Wednesday . The stock had previously closed at $0.13, but opened at $0.13. Cancer Genetics shares last traded at $0.12, with a volume of 90,390 shares trading hands.

The stock’s fifty day simple moving average is $0.16. The company has a quick ratio of 0.36, a current ratio of 0.36 and a debt-to-equity ratio of 0.24.

Cancer Genetics (NASDAQ:CGIX) last issued its quarterly earnings results on Monday, May 20th. The medical research company reported ($0.08) earnings per share for the quarter. The business had revenue of $6.84 million during the quarter. Cancer Genetics had a negative net margin of 77.28% and a negative return on equity of 175.72%.

A number of institutional investors and hedge funds have recently modified their holdings of CGIX. Perkins Capital Management Inc. increased its holdings in shares of Cancer Genetics by 649.9% during the 1st quarter. Perkins Capital Management Inc. now owns 3,136,528 shares of the medical research company’s stock worth $753,000 after buying an additional 2,718,278 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Cancer Genetics during the 1st quarter worth $48,000. Geode Capital Management LLC increased its holdings in shares of Cancer Genetics by 106.6% during the 4th quarter. Geode Capital Management LLC now owns 221,803 shares of the medical research company’s stock worth $53,000 after buying an additional 114,448 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Cancer Genetics by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 2,777,125 shares of the medical research company’s stock worth $453,000 after buying an additional 769,896 shares during the last quarter. Institutional investors own 10.56% of the company’s stock.

About Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Featured Article: How to Calculate Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.